Isolated amyloidosis of the lower urinary tract is rare. This report presents localised primary amyloidosis of the urinary bladder as a rare cause of macroscopic haematuria. Treatment of bladder amyloidosis mainly consists of controlling the haematuria. For small localised lesions, the favoured approach is transurethral resection (TUR) of the lesion.
Objective: To assess the efficacy of standard percutaneous nephrolithotripsy (PNL) in patients with large upper ureteric stones. Materials and methods:Between September 2009 and March 2011, 27 patients underwent standard PNL for renal stones or large upper ureteric stones. The stones were located between the ureteropelvic junction and 4th lumbar vertebra. Stone burden, success rate, operating time, access, hemoglobin drop, analgesic requirement, serum creatinine level, hospital stay, and complications were evaluated. Results:The mean stone burden was 374.1 mm 2 and the operating time was 73.3 min. The total success rate was 85.1%. Single access was used in 26 (96.2%) patients and a second access was necessary in 1 (3.8%) patient. Access was achieved to the upper, middle, and lower calix in 3 (10.7%), 21 (75%), and 4(14.3%) patients, respectively. The pre-and postoperative serum creatinine levels were 1.0±0.2 and 1.1±0.3 mg/dL, respectively (p>0.05). The mean hemoglobin decrease was 2.1 mg/dL, analgesic requirement was 230.7 mg, and hospital stay was 2.3 days. The total complication rate was 29.6%. Open surgery was required in 1 (3.7%) patient. The blood transfusion rate was 11.1%. Fever (>38.5°C), pelvic perforation, and prolonged urinary drainage were seen in 2 (7.4%), 1 (3.7%), and 1 (3.7%) patient, respectively. Auxiliary procedures were needed in 4 (14.9%) patients (extracorporeal shock wave lithotripsy in 2, and ureteroscopy and double J stenting in 1 patient each). Conclusion:PNL is still a reasonable procedure for treating large upper ureteric stones, and it can be performed safely with a favorable outcome in experienced hands. Key words:Complications; lithotripsy; percutaneous; treatment outcome; ureteral calculi. ÖZETAmaç: Büyük çaplı üst üreter taşı olan olgularda standart perkütan nefrolitotripsinin (PNL) etkinliğini değerlendirmek. Gereç ve yöntem:Eylül 2009 ile Mart 2011 tarihleri arasında 27 hastaya böbrek taşı ve/veya büyük çaplı üst üreter taşı nedeniyle standart PNL uygulandı. Taşların yerleşimi üreteropelvik bileşke ile 4. lomber vertebra arasında idi. Taş yükü, başarı oranı, operasyon süresi, giriş, hemoglobin düşüşü, analjezik gereksinimi, serum kreatinin düzeyi, hastanede kalış süresi ve komplikasyonlar değerlendirildi. Bulgular:Ortalama taş yükü 374.1 mm² ve operasyon süresi 73.3 dakika idi. Genel başarı oranı %85.1 idi. Hastaların 26'sına (%96.2) tek giriş ve 1'ine (%3.8) ise iki giriş yapıldı. Olguların 3'ünde (%10.7) üst kaliksten, 21'inde (%75) orta kaliksten, 4'ünde (%14.3) alt kaliksten giriş sağlandı. Operasyon öncesi serum kreatinin düzeyi 1.0±0.2 mg/dL ve operasyon sonrası serum kreatinin düzeyi ise 1.1±0.3 mg/dL idi (p>0.05). Ortalama hemoglobin düşüşü 2.1 mg/dL, ağrı kesici gereksinimi 230.7 mg ve hastanede kalış süresi 2.3 gün idi. Genel komplikasyon oranı %29.6 idi. Bir (%3.7) hastada açık cerrahi gereksinimi oldu. Kan transfüzyon oranı %11.1 idi. Ateş (>38.5°C), pelvik perforasyon ve uzamış idrar drenajı sırasıyla 2 (%7.4), 1 (%3.7), 1 (%3.7) olguda gözlendi. Yardımcı ...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.